VolitionRX 2026年季度报告

FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) 91-1949078(I.R.S. Employer Identification No.) 1489 West Warm Springs Road, Suite 110Henderson, Nevada(Address of principal executive offices) 89014(Zip Code) +1 (512) 774–8930(Registrant’s telephone number, including area code) N/A(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filer Accelerated filerSmaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).☐Yes☒No As of August 11, 2026, there were 13,649,384 shares of the registrant’s $0.001 par value common stock issued and outstanding. VOLITIONRX LIMITED QUARTERLY REPORT ON FORM 10-QFOR THE SIX MONTHS ENDED JUNE 30, 2026 TABLE OF CONTENTS PAGE PART IFINANCIAL INFORMATIONItem 1.FINANCIAL STATEMENTS (UNAUDITED)5Item 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS40Item 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK49Item 4.CONTROLS AND PROCEDURES49PART IIOTHER INFORMATIONItem 1.LEGAL PROCEEDINGS51Item 1A.RISK FACTORS51Item 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS51Item 3.DEFAULTS UPON SENIOR SECURITIES51Item 4.MINE SAFETY DISCLOSURES51Item 5.OTHER INFORMATION51Item 6.EXHIBITS52SIGNATURES53 Use of Terms Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q to the “Company,” “VolitionRx,”“Volition,” “we,” “us,” and “our” are references to VolitionRx Limited and its wholly owned subsidiaries, Volition Global ServicesSRL, Singapore Volition Pte. Limited, Belgian Volition SRL, Volition Diagnostics UK Limited, Volition America, Inc., and itsmajority-owned subsidiary, Volition Veterinary Diagnostics Development LLC. Additionally, unless otherwise specified, all referencesto “$” refer to the legal currency of the United States of America. NucleosomicsTM,, Capture-PCRTM, Nu.Q®and Capture-SeqTMand their respective logos are trademarks and/or service marks ofVolitionRx and its subsidiaries. All other trademarks, service marks and trade names referred to herein are the property of theirrespective owners. CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q for the quarterly period endedJune 30, 2026, (this “Report”) contains forward-lookingstatements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of theSecurities Exchange Act of 1934, as amended (the “Exchange Act”), which statements are subject to considerable risks anduncertainties. These forward-looking statements are intended to qualify for the safe harbor from liability established by the PrivateSecurities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Report or incorporatedby reference into this Report are forward-looking statements.We have attempted to identify forward-looking statements by using wordssuch as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate(s),” “expect,” “forecast(s),” “goal,” “intend,” “may,”“plan(s),” “potential,” “project,” “seek,” “should,” “strategy,” “will,” and other forms of these words or similar words orexpressions or the negative th